Prolongation of the QT interval related to cisapride-diltiazem interaction

Pharmacotherapy

Volumn 18, Issue 2 I, 1998, Pages 381-385

  Thomas, Audra R ^a   Chan, Lingtak Neander ^a   Bauman, Jerry L ^a,b   Olopade, Christopher O ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CISAPRIDE; CYTOCHROME P450; DILTIAZEM; ERYTHROMYCIN; METOCLOPRAMIDE;

ADULT; ARTICLE; CASE REPORT; ELECTROCARDIOGRAPHY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERTENSION; INHALATIONAL DRUG ADMINISTRATION; LONG QT SYNDROME; QT INTERVAL; SINUS TACHYCARDIA;

ANTIHYPERTENSIVE AGENTS; CISAPRIDE; CYTOCHROME P-450 ENZYME SYSTEM; DILTIAZEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HEART RATE; HUMANS; LONG QT SYNDROME; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PIPERIDINES;

EID: 0031953555     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993;12(1):1-51.
2. Daly AK, Brockmoller J, Broly F, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
3. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;5:1-42.
4. Wiseman LR, Faulds D. Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994;47:116-52.
5. Bedford TA, Rowbotham DJ. Cisapride: drug interactions of clinical significance. Drug Safety 1996;15(3):167-75.
6. Pettignano R, Chambliss CR, Darsey E, Heard M, Clark R. Cisapride-induced dysrhythmia in a pediatric patient receiving extracorporeal life support. Crit Care Med 1996;24(7): 1268-71.
7. Lewin MB, Bryant RM, Fenrich AL, Grifka RG. Cisapride-induced long QT interval. J Pediatr 1996;128:279-81.
8. Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995;155:765-8.
9. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia [letter]. N Engl J Med 1996;335:290-1.
10. Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18(5):595-606.
11. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995;104:1-8.
12. Murray M, Butler AM. Enhanced inhibition of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation. J Pharmacol Exp Ther 1996;279(3): 1447-52.
13. Faber TS, Zehender M, Just H. Drug-induced torsades de pointes: incidence, management and prevention. Drug Safety 1994;11(6):463-76.
14. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264:2788-90.
15. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6.
16. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LF. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-18.
17. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8.
18. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of thirty Japanese and thirty Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
19. Wu CY, Benet LZ, Herbert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-7.
20. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-19.
21. Bockaert J, Fozard JR, Dumuis A, Clarke DE. The 5-HT4 receptor: a place in the sun. Trends Pharmacol Sci 1992; 13:141-5.
22. Kaumann AJ, Sanders L, Brown AM, Murray KJ, Brown MJ. A 5-HT4-like receptor in human right atrium. Naunyn Schmiedebergs Arch Pharmacol 1991;344:150-9.
23. Janssen Pharmaceutica. Propulsid (cisapride) package insert. Titusville, NJ; 1995.
24. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 1991;41(12): 1911-19.
25. Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 1996;59:369-75.
26. Laganiere S, Davies RF, Carignan G, et al. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. Clin Pharmacol Ther 1996;60:255-64.
27. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986;30:287-95.
28. Zanger UM, Vilbois F, Hardwick J, Meyer UA. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988;27: 5447-54.
29. Riesenman C. Antidepressant drug interactions and cytochrome P450 system: a critical appraisal. Pharmacotherapy 1995;15(6 Pt 2):84S-99.
30. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996;16:104-12.
31. Bergstrom RF, Goldberg MJ, Cerimele BJ, Hatcher BL. Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin Pharmacol Ther 1997;62:643-51.
32. Gidal BE, Anderson GD, Seaton TL, Miyoshi HR, Wilensky AJ. Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide. Ther Drug Monit 1993;15:405-9.
33. Anderson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991;21(3):195-212.
34. Anderson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31(1):9-28.